Boston Scientific Price Targets Cut to $64 and $55 as Shares Near 52-Week Low
BSX•Truist cut its price target for Boston Scientific from $85 to $64, while Wells Fargo downgraded its rating to Equal-Weight and lowered its target to $55. Shares slid 15% to about $49.30, near a 52-week low, despite management reaffirming 2026 organic revenue growth guidance of 6.5%–8%.
1. Analyst Price Target Cuts
On June 4, Truist Financial cut its price target for Boston Scientific from $85 to $64, projecting a 29.7% upside from current levels. Wells Fargo downgraded the rating to Equal-Weight and reduced its target from $75 to $55.
2. Stock Performance Decline
Shares declined about 15% over the past week to approximately $49.30, approaching a 52-week low of $47.17 and far below the $109.50 high. The market capitalization stands near $73.3 billion following the pullback.
3. Management Reaffirms Guidance
Despite Watchman heart implant revenue expected to remain flat in upcoming quarters, management confirmed full-year 2026 organic revenue growth guidance of 6.5%–8%. The company cited strength in other medical device franchises to support this outlook.
